OUR VISION
Micregen has developed an award-winning platform technology to manipulate stem cells to produce multifunctional, 'off-the-shelf’, secretome products aimed at addressing underdevelopment conditions and degenerative processes that are the main cause of many diseases.
Developing disease-modifying cell-free treatments that harness the potent combination of stem cell paracrine factors, including miRNA, extracellular vesicles (inc. exosomes), and proteins (e.g. growth factors)
To date, addressing the complex challenges of underdevelopment and degenerative conditions has proved difficult. Most current disease treatments focus on a single facet of the condition and often target its symptoms rather than the root cause. As a result, many diseases currently only receive symptomatic treatment, failing to address the underlying mechanisms of disease progression.
Most diseases are the result of continuous cell and molecular changes, affecting tissues or organs, and increasingly deteriorate over time. Complex solutions are required.
We refer to the products that our proprietary platform produces as Secretomix®.
Our research has demonstrated that they display disease modifying capabilities through their multi-modal action, modulating critical factors in cellular degeneration, including inflammation, cellular senescence, altered intercellular communication, stem cell exhaustion and compromised autophagy.
By targeting multiple pathological pathways simultaneously, we believe they offer a unique and comprehensive approach to treating complex diseases.
History
The use of stem cell-based therapy in the field of regenerative medicine is considered one of the most promising medical approaches. However, research into whole mesenchymal stem cell transplantation therapy has identified limitations to this area of study.
Research has shown that the paracrine factors secreted from stem cells were mainly responsible for the repair and regeneration of tissue, rather than the whole cell itself. This finding, with further development over two decades, has gained widespread acceptance in published literature.
Micregen’s research focuses on the production of stem cell-derived multifunctional secretomes from a single cell source, to produce therapeutics that could be potentially used by everyone (allogeneic).
Micregen has created a GMP cell bank that can supply unlimited stem cells without the need to continually collect fresh tissue from donors. This tackles the historically challenges, including product variability.
Secretomix® can be scaled, manufactured consistently, stored long-term without the need for ultra-cold conditions, and administered immediately at the point of care.
Secretomix® offers great potential for regenerative medicine and patient care. Through the secretome’s ability to simultaneously act on numerous cell-signaling pathways, Micregen aims to provide a novel treatment for multiple conditions.
The Secretomix® platform is designed to create various secretome formulations.
Secretomix® are multi-component biologics (including components like miRNA, Exosomes, Cytokines, Anti-inflammatory factors, lipids and proteins, including growth factors), which act to enhance multiple aspects of tissue repair and regeneration, and modulating several mechanisms.
Stem cell secretomes have been proven to stimulate tissue repair, modulate inflammation and scarring, improve blood flow, and generate a pro-regenerative micro-environment across various organs and tissue types (Tran and Damaser 2015, Kusuma, Carthew et al. 2017, Haque N. 2018).
The Extracellular Vesicle (EV) component of Micregen’s product is able to access many areas of the body to facilitate repair and regeneration. Interestingly, certain secretome EVs have been shown to cross the Blood Brain Barrier, providing the potential to treat certain neurological diseases (Ramos-Zaldívar, Polakovicova et al. 2022).
Micregen believes that their innovative approach in developing the Secretomix® platform to produce various optimised secretome formulations from its first GMP master and working cell banks, could change how a number of critical and chronic diseases are managed.